Climb Bio, Inc. (NASDAQ:CLYM) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Climb Bio, Inc. (NASDAQ:CLYM) have earned an average rating of “Buy” from the eleven analysts that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, seven have issued a buy rating and three have issued a strong buy rating on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $15.6250.

CLYM has been the subject of a number of recent analyst reports. Piper Sandler began coverage on Climb Bio in a research report on Friday, February 13th. They set an “overweight” rating for the company. Raymond James Financial began coverage on Climb Bio in a research report on Tuesday, March 10th. They issued a “strong-buy” rating and a $25.00 price target on the stock. B. Riley Financial began coverage on Climb Bio in a research note on Tuesday. They issued a “buy” rating and a $26.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Climb Bio in a research report on Wednesday, January 21st. Finally, HC Wainwright increased their price objective on shares of Climb Bio from $11.00 to $15.00 and gave the stock a “buy” rating in a research note on Tuesday, March 10th.

Climb Bio Trading Down 1.3%

NASDAQ CLYM opened at $7.02 on Friday. Climb Bio has a 1-year low of $1.05 and a 1-year high of $8.04. The company has a 50 day moving average of $6.05 and a 200-day moving average of $3.80. The company has a market cap of $335.35 million, a price-to-earnings ratio of -7.89 and a beta of -0.25.

Climb Bio (NASDAQ:CLYM) last issued its quarterly earnings results on Thursday, March 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.06). On average, equities research analysts forecast that Climb Bio will post -1.57 earnings per share for the current year.

Institutional Trading of Climb Bio

Several large investors have recently made changes to their positions in the company. Peapod Lane Capital LLC raised its position in Climb Bio by 0.7% during the fourth quarter. Peapod Lane Capital LLC now owns 565,992 shares of the company’s stock valued at $2,264,000 after purchasing an additional 4,126 shares in the last quarter. XTX Topco Ltd increased its stake in shares of Climb Bio by 19.4% in the 4th quarter. XTX Topco Ltd now owns 34,852 shares of the company’s stock valued at $139,000 after purchasing an additional 5,668 shares during the last quarter. Virtu Financial LLC acquired a new position in shares of Climb Bio during the 4th quarter worth $43,000. Blair William & Co. IL acquired a new position in shares of Climb Bio during the 4th quarter worth $44,000. Finally, Hsbc Holdings PLC lifted its position in shares of Climb Bio by 107.2% during the 4th quarter. Hsbc Holdings PLC now owns 24,744 shares of the company’s stock worth $99,000 after buying an additional 12,800 shares during the last quarter. Institutional investors and hedge funds own 69.76% of the company’s stock.

Climb Bio Company Profile

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.